MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

493.32
-5.43
-1.09%
After Hours: 497.00 +3.68 +0.75% 19:27 04/03 EDT
OPEN
495.56
PREV CLOSE
498.75
HIGH
503.26
LOW
485.04
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
518.00
52 WEEK LOW
271.37
MARKET CAP
54.27B
P/E (TTM)
26.71
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REGN stock price target is 476.21 with a high estimate of 600.00 and a low estimate of 370.00.

EPS

REGN News

More
  • Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
  • seekingalpha · 6h ago
  • U.K. Prime Minister Boris Johnson Admitted to Hospital with Persistent Coronavirus Symptoms
  • Barrons.com · 8h ago
  • Should You Buy Inovio Pharmaceuticals During the Coronavirus Market Crash?
  • MotleyFool.com · 12h ago
  • Theres scant evidence so far for chloroquine as a COVID-19 drug but theres already a shortage
  • MarketWatch · 15h ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
More

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.